Kaestner, Lena http://orcid.org/0000-0002-4696-6332
Boda-Heggemann, Judit
Fanslau, Hannah
Xie, Jingyang
Schweikard, Achim
Giordano, Frank A.
Blanck, Oliver
Rudic, Boris
Funding for this research was provided by:
Horizon 2020 Framework Programme (945119)
Ruprecht-Karls-Universität Heidelberg
Article History
Received: 6 June 2023
Accepted: 7 August 2023
First Online: 12 September 2023
Declarations
:
: <i>Financial interests:</i> L. Kaestner: Speaker honoraria AstraZeneca GmbH. J. Boda-Heggemann: EBAMed consulting fees outside of the study, Elekta research grant outside the study, speaker honoraria AstraZeneca GmbH. F.A. Giordano: Honoraria, research grants and/or travel support from Carl Zeiss Meditec AG, TME Pharma AG, Guerbet SA, Cureteq AG, Bristol-Myers Squibb, AstraZeneca GmbH, FoMF GmbH, MEDAC GmbH, Elsevier GmbH and stock/ownership from TME Pharma AG and Implacit GmbH outside the submitted work. <i>Non-financial interests</i>: O. Blanck is a section editor in the journal <i>Strahlentherapie und Onkologie</i>. H. Fanslau, J. Xie, A. Schweikard and B. Rudic declare that they have no competing interests.
: <i>Ethics approval: </i>Approval was obtained from the ethics committee of University Heidelberg-Mannheim and Kiel. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. <i>Consent to participate/publish:</i> Informed consent was obtained from all individual participants included in the study. The participant has consented to the submission of the case report to the journal.